Evidence map›Paper›PMID 35737276›Full record

ReviewActa neurologica Belgica2023

Granulocyte-colony stimulating factor (G-CSF): an emerging therapeutic approach for amyotrophic lateral sclerosis (ALS).

Mahsa Vafaei Mastanabad, Aref Nooraei, Mahgol Sadat Hassan Zadeh Tabatabaei, Amir Akbari Fakhrabadi, Faria Jafarzadeh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Acta neurologica Belgica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Mahsa Vafaei MastanabadMedical Doctor of Saveh Healthcare Network, Saveh, Iran.
Aref NooraeiComparative Anatomy and Embryology, School of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
Mahgol Sadat Hassan Zadeh TabatabaeiSchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Amir Akbari FakhrabadiResearch Committee, Medical School, Arak University of Medical Sciences, Arak, Iran.
Faria JafarzadehDepartment of Internal Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnourd, Iran. f.Jafarzadeh@nkums.ac.ir.ORCID http://orcid.org/0000-0002-8412-2405
Arak University of Medical Sciences · IRNorth Khorasan University of Medical Sciences · IRSaveh University of Medical Sciences · IRShahid Chamran University of Ahvaz · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by neuronal degeneration and inflammation in the nerves. G-CSF is a 19.6-kDa hematopoietic growth factor which is essential for the proliferation and differentiation of granulocyte hematopoietic progenitors. G-CSF exerts neuroprotective activities by induction of neuronal regeneration, inhibition of neuronal apoptosis, mobilization of Hematopoietic stem cells (HSCs), regulation of pro and anti-inflammatory cytokines, and activation of angiogenesis. Pre-clinical studies have shown significant efficacy of G-CSF therapy in mSOD1

Indexed as

Amyotrophic Lateral SclerosisAnimalsCytokinesGranulocyte Colony-Stimulating FactorGranulocytesHematopoietic Stem CellsMiceCytokinesGranulocyte Colony-Stimulating FactorAmyotrophic lateral sclerosis (ALS)Granulocyte-colony stimulating factor (G-CSF)

Identifiers

PMID35737276
OpenAlexW4283322336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.